Jiale Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiale Chen has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Guoquan Chen
Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China
4 shared publications - Wenxing Peng
Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
2 shared publications Bangbiao Ge
Information Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China
1 shared publicationHaiping Wang
Department of Pharmacy, Longyan Second Hospital, Longyan, People’s Republic of China
1 shared publication- Hejian Guo
Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
1 shared publication Jiahao Ye
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
External Validation and Bayesian Forecasting of Rivaroxaban Population Pharmacokinetic Models in Older Chinese Patients with Nonvalvular Atrial Fibrillation
Background: Population pharmacokinetic (PopPK) models have been developed to characterize rivaroxaban exposure; however, their transferability across different clinical populations remains uncertain. This study aimed to externally evaluate published rivaroxaban PopPK models in older Chinese patients with nonvalvular atrial fibrillation (NVAF) and assess whether Bayesian forecasting could improve individual concentration prediction. Methods: Six published rivaroxaban PopPK models were evaluated using an independent cohort from the RIVA-GAP study. Predictive performance was assessed using prediction error metrics reflecting bias, precision, and prediction coverage, together with normalized prediction distribution error (NPDE) diagnostics. Bayesian forecasting was performed using paired steady-state trough–peak concentrations to evaluate changes in individual peak concentration prediction. Results: A total of 135 patients with 257 rivaroxaban concentration observations were included for external validation, and 122 patients with paired trough–peak samples were included for Bayesian forecasting. Predictive performance varied substantially among the six models, and none consistently met predefined acceptance criteria. Model A showed comparatively lower prediction bias among the evaluated models but still demonstrated limited precision (MDPE 33.64%, MDAPE 53.72%, F30 31.52%). Bayesian forecasting reduced the MDIPE of Model A from 33.64% to 12.38%, but MAIPE remained 37.33% and IF30 was 41.8%. Similar model-dependent effects were observed across the other models. Conclusion: Published rivaroxaban PopPK models demonstrated heterogeneous transferability in older Chinese patients with NVAF. Bayesian forecasting using a single trough concentration provided modest and model-dependent improvement in concentration prediction but did not consistently overcome limitations of the underlying models. Clinical Trial/Study Registration: Chinese Clinical Trial Registry, ChiCTR2300074934; registered 21 August 2023.
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Open AccessExternal Validation and Bayesian Forecasting of Rivaroxaban Population Pharmacokinetic Models in Older Chinese Patients with Nonvalvular Atrial Fibrillation
Background: Population pharmacokinetic (PopPK) models have been developed to characterize rivaroxaban exposure; however, their transferability across different clinical populations remains uncertain. This study aimed to externally evaluate published rivaroxaban PopPK models in older Chinese patients with nonvalvular atrial fibrillation (NVAF) and assess whether Bayesian forecasting could improve individual concentration prediction. Methods: Six published rivaroxaban PopPK models were evaluated using an independent cohort from the RIVA-GAP study. Predictive performance was assessed using prediction error metrics reflecting bias, precision, and prediction coverage, together with normalized prediction distribution error (NPDE) diagnostics. Bayesian forecasting was performed using paired steady-state trough–peak concentrations to evaluate changes in individual peak concentration prediction. Results: A total of 135 patients with 257 rivaroxaban concentration observations were included for external validation, and 122 patients with paired trough–peak samples were included for Bayesian forecasting. Predictive performance varied substantially among the six models, and none consistently met predefined acceptance criteria. Model A showed comparatively lower prediction bias among the evaluated models but still demonstrated limited precision (MDPE 33.64%, MDAPE 53.72%, F30 31.52%). Bayesian forecasting reduced the MDIPE of Model A from 33.64% to 12.38%, but MAIPE remained 37.33% and IF30 was 41.8%. Similar model-dependent effects were observed across the other models. Conclusion: Published rivaroxaban PopPK models demonstrated heterogeneous transferability in older Chinese patients with NVAF. Bayesian forecasting using a single trough concentration provided modest and model-dependent improvement in concentration prediction but did not consistently overcome limitations of the underlying models. Clinical Trial/Study Registration: Chinese Clinical Trial Registry, ChiCTR2300074934; registered 21 August 2023.
- 11 December 2024
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- p. 1-10
Oral anticoagulants-induced intracranial hemorrhage: a real-world pharmacovigilance study over 2008–2024
- 11 December 2024
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- p. 1-10
Oral anticoagulants-induced intracranial hemorrhage: a real-world pharmacovigilance study over 2008–2024
- Open Access
- 1 May 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 1573-1582
Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation
Objective: Atrial fibrillation (AF) is the most common abnormal heart rhythm in elderly patients. Rivaroxaban has been widely used for stroke prevention. The anticoagulant response to rivaroxaban increases with age, which may make elderly patients susceptible to adverse outcomes resulting from small differences in bioavailability between generic and brand products. Methods: We designed a cohort study of ≥ 65-year-old inpatients with AF. Sociodemographic and laboratory measures of qualified patients who received brand or generic rivaroxaban for at least 72 hours at the study hospital from January 2021 to June 2023 were collected retrospectively. The primary outcome was the incidence of bleeding. Results: A total of 1008 qualifying patients were included for analysis, with 626 (62.1%) receiving brand rivaroxaban and 382 (37.9%) receiving generic rivaroxaban. After propensity score matching and weighting to account for confounders, the odds ratios comparing brand vs generic rivaroxaban (95% confidence intervals) for the bleeding was 1.15 (0.72– 1.82). Results from subgroup analyses of patients with age ≥ 85, HAS-BLED score ≥ 3, containment of antiplatelet drugs, and female patients were consistent with the primary analysis. Conclusion: It provides evidence regarding the clinical safety outcome of generic rivaroxaban in the elderly AF population that may be particularly susceptible to adverse outcomes resulting from small allowable differences in pharmacokinetics.
- 1 May 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 1573-1582
Open AccessComparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation
Objective: Atrial fibrillation (AF) is the most common abnormal heart rhythm in elderly patients. Rivaroxaban has been widely used for stroke prevention. The anticoagulant response to rivaroxaban increases with age, which may make elderly patients susceptible to adverse outcomes resulting from small differences in bioavailability between generic and brand products. Methods: We designed a cohort study of ≥ 65-year-old inpatients with AF. Sociodemographic and laboratory measures of qualified patients who received brand or generic rivaroxaban for at least 72 hours at the study hospital from January 2021 to June 2023 were collected retrospectively. The primary outcome was the incidence of bleeding. Results: A total of 1008 qualifying patients were included for analysis, with 626 (62.1%) receiving brand rivaroxaban and 382 (37.9%) receiving generic rivaroxaban. After propensity score matching and weighting to account for confounders, the odds ratios comparing brand vs generic rivaroxaban (95% confidence intervals) for the bleeding was 1.15 (0.72– 1.82). Results from subgroup analyses of patients with age ≥ 85, HAS-BLED score ≥ 3, containment of antiplatelet drugs, and female patients were consistent with the primary analysis. Conclusion: It provides evidence regarding the clinical safety outcome of generic rivaroxaban in the elderly AF population that may be particularly susceptible to adverse outcomes resulting from small allowable differences in pharmacokinetics.
- 11 August 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (10) , 1084-1093
Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta‐analysis and systematic review
Objectives: Extracorporeal membrane oxygenation (ECMO) plays an important role in providing temporary life support for patients with severe cardiac or pulmonary failure, but requires strict anticoagulation and monitoring. This network meta‐analysis systematically explored the most effective anticoagulation and monitoring strategies for patients receiving ECMO.Methods: MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched up to January 31, 2023, for studies comparing unfractionated heparin (UFH), argatroban (Arg), bivalirudin (Biv), and/or nafamostat mesylate (NM) in patients receiving ECMO. The primary outcomes included device‐related thrombosis, patient‐related thrombosis, and major bleeding events. The secondary outcomes included ECMO survival, ECMO duration, and in‐hospital mortality.Results: A total of 2522 patients from 23 trials were included in the study. Biv was associated with a decreased risk of device‐related thrombosis (odd ratio [OR] 0.51, 95% confidence interval [CI]: 0.33–0.84) compared with UFH, whereas NM (OR 2.2, 95% CI: 0.24–65.0) and Arg (OR 0.92, 95% CI: 0.43–2.0) did not reduce the risk of device‐related thrombosis compared with UFH. Biv was superior to Arg in decreasing the risk of device‐related thrombosis (OR 0.14, 95% CI: 0.03–0.51). Biv reduced the risk of patient‐related thrombosis compared with UFH (OR 0.44, 95% CI: 0.18–0.85); NM (OR 0.65, 95% CI: 0.14–3.3) and Arg (OR 3.1, 95% CI: 0.94–12.0) did not decrease risk of patient‐related thrombosis compared with UFH. No significant difference was observed in the risk of major bleeding between three alternatives and UFH: Biv (OR 0.54, 95% CI: 0.23–1.3), Arg (OR 1.3, 95% CI: 0.34–5.8), and NM (OR 0.60, 95% CI: 0.13–2.6). NM showed a reduced risk of in‐hospital mortality compared with UFH (OR 0.27, 95% CI: 0.091–0.77), whereas Arg (OR 0.43, 95% CI: 0.15–1.2) and Biv (OR 0.75, 95% CI: 0.52–1.1) did not decrease risk of in‐hospital mortality.Conclusions: Compared with UFH and Arg, Biv reduces the risk of thrombosis and appears to be a better choice for patients requiring ECMO. NM was associated with a reduced risk of in‐hospital mortality.
- 11 August 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (10) , 1084-1093
Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta‐analysis and systematic review
Objectives: Extracorporeal membrane oxygenation (ECMO) plays an important role in providing temporary life support for patients with severe cardiac or pulmonary failure, but requires strict anticoagulation and monitoring. This network meta‐analysis systematically explored the most effective anticoagulation and monitoring strategies for patients receiving ECMO.Methods: MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched up to January 31, 2023, for studies comparing unfractionated heparin (UFH), argatroban (Arg), bivalirudin (Biv), and/or nafamostat mesylate (NM) in patients receiving ECMO. The primary outcomes included device‐related thrombosis, patient‐related thrombosis, and major bleeding events. The secondary outcomes included ECMO survival, ECMO duration, and in‐hospital mortality.Results: A total of 2522 patients from 23 trials were included in the study. Biv was associated with a decreased risk of device‐related thrombosis (odd ratio [OR] 0.51, 95% confidence interval [CI]: 0.33–0.84) compared with UFH, whereas NM (OR 2.2, 95% CI: 0.24–65.0) and Arg (OR 0.92, 95% CI: 0.43–2.0) did not reduce the risk of device‐related thrombosis compared with UFH. Biv was superior to Arg in decreasing the risk of device‐related thrombosis (OR 0.14, 95% CI: 0.03–0.51). Biv reduced the risk of patient‐related thrombosis compared with UFH (OR 0.44, 95% CI: 0.18–0.85); NM (OR 0.65, 95% CI: 0.14–3.3) and Arg (OR 3.1, 95% CI: 0.94–12.0) did not decrease risk of patient‐related thrombosis compared with UFH. No significant difference was observed in the risk of major bleeding between three alternatives and UFH: Biv (OR 0.54, 95% CI: 0.23–1.3), Arg (OR 1.3, 95% CI: 0.34–5.8), and NM (OR 0.60, 95% CI: 0.13–2.6). NM showed a reduced risk of in‐hospital mortality compared with UFH (OR 0.27, 95% CI: 0.091–0.77), whereas Arg (OR 0.43, 95% CI: 0.15–1.2) and Biv (OR 0.75, 95% CI: 0.52–1.1) did not decrease risk of in‐hospital mortality.Conclusions: Compared with UFH and Arg, Biv reduces the risk of thrombosis and appears to be a better choice for patients requiring ECMO. NM was associated with a reduced risk of in‐hospital mortality.